Copyright
©2011 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. May 7, 2011; 17(17): 2255-2258
Published online May 7, 2011. doi: 10.3748/wjg.v17.i17.2255
Published online May 7, 2011. doi: 10.3748/wjg.v17.i17.2255
Neoadjuvant sorafenib combined with gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma
Nicolas Williet, Olivier Dubreuil, Tarek Boussaha, Isabelle Trouilloud, Bruno Landi, Philippe Rougier, Julien Taieb, Department of Gastroenterology, Europeen Georges Pompidou Hospital, Medical University, 75908 Paris, France
Martin Housset, Muriel Botti, Department of Radiotherapy, Europeen Georges Pompidou Hospital, Medical University, 75908 Paris, France
Jacques Belghiti, Beaujon Hôspital, Medical University, 100, boulevard du Général Leclerc, 92110 Clichy, France
Author contributions: All authors contributed equally to this work; Williet N wrote the paper.
Correspondence to: Nicolas Williet, MD, Department of Gastroenterology, Europeen Georges Pompidou Hospital, Medical University, 20 rue Leblanc, 75908 Paris, France. nwilliet@yahoo.fr
Telephone: +33-1-56092822 Fax: +33-1-56093529
Received: November 2, 2010
Revised: January 18, 2011
Accepted: January 25, 2011
Published online: May 7, 2011
Revised: January 18, 2011
Accepted: January 25, 2011
Published online: May 7, 2011
Abstract
This paper reports the first case of a patient with hepatocellular carcinoma with lymph node metastasis treated by sorafenib combined with gemcitabine plus oxaliplatin, with a partial response and normalization of α fetoprotein, which allowed curative surgery. The potential synergy between these three drugs needs to be confirmed, and is currently being investigated in a randomized phase II trial.